Search Result

Pathways Recommended:	JAK/STAT Signaling

Results for "

JAK kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (112) Ack1 (1) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (31) Aurora Kinase (8) Autophagy (5) Bcl-2 Family (1) Bcr-Abl (6) BMX Kinase (1) Btk (7) c-Myc (2) Cannabinoid Receptor (1) Caspase (1) CDK (4) CXCR (1) Cytochrome P450 (1) EGFR (7) Epigenetic Reader Domain (1) ERK (1) Ferroptosis (1) FGFR (2) FLT3 (11) Fluorescent Dye (1) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione Peroxidase (1) GSK-3 (4) HDAC (1) IFNAR (7) IGF-1R (1) Influenza Virus (1) Interleukin Related (13) IRAK (2) Isotope-Labeled Compounds (6) Itk (1) Keap1-Nrf2 (1) LRRK2 (1) MEK (2) Microtubule/Tubulin (1) Mitosis (2) mRNA (2) NADH Dehydrogenase (1) NF-κB (3) p38 MAPK (2) Parasite (2) PARP (1) PDGFR (1) PI3K (3) Polo-like Kinase (PLK) (1) Protease Activated Receptor (PAR) (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (10) RET (4) ROS Kinase (1) Src (2) STAT (30) Syk (8) TAM Receptor (1) TGF-β Receptor (1) Thrombopoietin Receptor (2) TNF Receptor (2) Trk Receptor (1) VEGFR (2) Virus Protease (2) Wnt (2)
By Research Areas:	Cancer (72) Cardiovascular Disease (4) Endocrinology (2) Infection (5) Inflammation/Immunology (61) Metabolic Disease (2)
Oligonucleotides:	mRNA (2) Interleukin & Receptors (2)

135

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: JAK

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-19569

Upadacitinib 25+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10409

Fedratinib 50+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and **JAK2V617F kinase*. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis* and has the potential for myeloproliferative disorders research .

HY-117287

Deucravacitinib Maximum Cited Publications 33 Publications Verification BMS-986165	JAK STAT Interleukin Related IFNAR	Inflammation/Immunology
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-100754

Ritlecitinib 5+ Cited Publications PF-06651600	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent *JAK3* inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-12000

AG490 Maximum Cited Publications 165 Publications Verification Tyrphostin AG490; Tyrphostin B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-14435

Pyridone 6 10+ Cited Publications	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for *JAK2* and TYK2, 5 nM for *JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases*.

HY-112708

Brepocitinib 3 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-103018

Gusacitinib 1 Publications Verification ASN-002	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) is an orally active dual *SYK/JAK* kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, *JAK1, JAK2, JAK3* and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10409A

Fedratinib hydrochloride hydrate 50+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and **JAK2V617F kinase*. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis* and has the potential for myeloproliferative disorders research .

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-10411

AZ960 1 Publications Verification	JAK Apoptosis Parasite Virus Protease	Cancer
AZ960 is a potent and specific inhibitor of the *JAK2* kinase with a K_i of 0.45 nM.

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-101976

JAK3-IN-6	JAK	Inflammation/Immunology
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

HY-15480

NSC 42834 3 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase* activity.

HY-19569R

Upadacitinib (Standard) 1 Publications Verification ABT-494 (Standard)	Reference Standards JAK	Inflammation/Immunology
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-100754C

Ritlecitinib tosylate 5+ Cited Publications PF-06651600 tosylate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent *JAK3* inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-112708A

Brepocitinib P-Tosylate 3 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, *JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-153701S

Envudeucitinibum Envudeucitinib; ESK-001	JAK Interleukin Related IFNAR Isotope-Labeled Compounds	Inflammation/Immunology
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-80002

BMX-IN-1 5+ Cited Publications BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of *bone marrow tyrosine kinase* on chromosome X (BMX) that targets Cys ⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀** of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

HY-169326S

JAK2-IN-11	Isotope-Labeled Compounds JAK	Cancer
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-113787

(R)-9b	Ack1 JAK	Cancer
(R)-9b is a potent inhibitor of ACK1 tyrosine kinase (IC₅₀=56 nM) with anticancer activity. (R)-9b exhibits selectivity for ACK1 but has inhibitory effects on JAK family kinases *JAK2* and Tyk2. (R)-9b can be used in the study of hormone-regulated cancers such as prostate and breast cancer .

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-174280

Modzatinib ITK kinase-IN-1	Itk JAK	Inflammation/Immunology
Modzatinib (ITK kinase-IN-1) is an oral active, selective, covalent *ITK/JAK3* dual-target inhibitor with IC₅₀ values of 8 nM and 23 nM, respectively. Modzatinib exhibits anti-inflammatory activity and can be used in the research of autoimmune and inflammatory diseases .

HY-109178

Ifidancitinib 1 Publications Verification ATI-50002; ATI-502	JAK	Others Inflammation/Immunology
Ifidancitinib (ATI-50002) is an orally available, potent and selective inhibitor of JAK kinase 1/3 that disrupts γc cytokine signaling. Ifidancitinib is used in the research of allergy, asthma, and autoimmune diseases .

HY-148785

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

HY-164393

ON044580	JAK Bcr-Abl Apoptosis	Cancer
ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive *JAK2* kinase inhibitor with IC₅₀s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 ^V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-148791

Pumecitinib PG-011	JAK	Inflammation/Immunology Cancer
Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib shows anti-inflammatory activity .

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-125019

iJak-381	JAK STAT	Inflammation/Immunology
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .

HY-P1590

*Tyrosine Protein Kinase* JAK 2 (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-177131

Soficitinib	JAK	Inflammation/Immunology
Soficitinib (Compound 20) is a selective tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) inhibitor, with IC₅₀ values of 0.5 nM and 1.2 nM, respectively. Soficitinib shows promise for research into autoimmune diseases (such as psoriasis, rheumatoid arthritis) and inflammatory diseases .

HY-145029

SYK/JAK-IN-1	Syk JAK	Cancer
SYK/JAK-IN-1 is a dual *Syk/Jak2* kinase inhibitor. SYK/JAK-IN-1 is applicable to cancer-related research .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-107594

Benzene hexabromide 1 Publications Verification	JAK	Cancer
Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of *JAK2* tyrosine kinase autophosphorylation.

HY-10409R

Fedratinib (Standard) TG-101348 (Standard); SAR 302503 (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-E70873

Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). Tyk2(JH1/JH2) Recombinant Human Active Protein Kinase is a recombinant Tyk2(JH1/JH2) protein that can be used to study Tyk2(JH1/JH2)-related functions .

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

HY-16449

SB1578 CT-1578	JAK FLT3	Inflammation/Immunology
SB1578 (CT-1578) is a selective *JAK2* and FLT3 inhibitor with an IC₅₀ of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis .

HY-14986

JAK-IN-32	JAK	Others
JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase .

HY-14435R

Pyridone 6 (Standard)	JAK Reference Standards	Cancer
Pyridone 6 (Standard) is the analytical standard of Pyridone 6. This product is intended for research and analytical applications. Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-P5434

Jak3tide JAK3 Peptide substrate	JAK	Others
Jak3tide (JAK3 Peptide substrate) is a biological active peptide. (This peptide is a substrate for Jak3. It may be used used in kinase assays. Jak3tide contains the phosphorylation site at Tyr7.)

HY-103018A

Gusacitinib hydrochloride ASN-002 hydrochloride	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) hydrochloride is an orally active dual *SYK/JAK* kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, *JAK1, JAK2, JAK3* and TYK2, respectively. Gusacitinib hydrochloride rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib hydrochloride can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-107459

(E/Z)-AG490 1 Publications Verification (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42	EGFR STAT JAK	Cancer
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

Cat. No.	Nombre del producto

HY-L008

JAK/STAT Compound Library

704 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 704 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L017

Stem Cell Signaling Compound Library

2,723 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 2,723 compounds that can be used for stem cell regulatory and signaling pathway research.

HY-L156

Autoimmune Disease Compound Library

958 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 958 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Nombre del producto	Target	Research Area

HY-P10373

pJAK2(1001-1013)	JAK IFNAR Interleukin Related	Infection Inflammation/Immunology
pJAK2(1001-1013) is a cell-penetrating peptide that corresponds to the activation loop of JAK2 tyrosine kinase and functions as a SOCS1/3antagonist. pJAK2 (1001-1013) blocks SOCS1-mediated negative regulation of immune function, and enhances the biological activity of cytokines such as IFNγ and IL6. pJAK2(1001-1013) inhibits the replication of a broad range of viruses and exerts dose-dependent protective efficacy against lethal viral infections. pJAK2(1001-1013) can be used for the study of immune regulation and infection .

HY-P1590

*Tyrosine Protein Kinase* JAK 2 (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-P5434

Jak3tide JAK3 Peptide substrate	JAK	Others
Jak3tide (JAK3 Peptide substrate) is a biological active peptide. (This peptide is a substrate for Jak3. It may be used used in kinase assays. Jak3tide contains the phosphorylation site at Tyr7.)

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-116035

Nimbolide 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Disease Research Fields Source Classification Cancer	Wnt NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N0818

Chikusetsusaponin Iva 2 Publications Verification Calenduloside F	Triterpenes Classification of Application Fields Terpenoids Other Diseases Amaranthaceae Plants Alternanthera philoxeroides (Mart.) Griseb. Disease Research Fields Source Classification	Keap1-Nrf2
Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a K_D value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, *JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV* and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects .

HY-N7694

Isotoosendanin 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Melia toosendan Sieb. et Zucc. Plants Meliaceae Inflammation/Immunology Disease Research Fields Source Classification	TGF-β Receptor JAK STAT Apoptosis
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the *JAK/STAT3* signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-116035R

Nimbolide (Standard)	Triterpenes Structural Classification Terpenoids Azadirachta indica A. Juss. Plants Meliaceae Source Classification	Wnt NF-κB CDK Apoptosis Reference Standards
Nimbolide (Standard) is the analytical standard of Nimbolide. This product is intended for research and analytical applications. Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-N14094

Tubulosine	Structural Classification Alkaloids Other Alkaloids Rubiaceae Plants Pogonopus tubulosus (A.Rich. ex DC.) K.Schum. Source Classification	JAK Apoptosis Autophagy
Tubulosine is an alkaloid. Tubulosine can be isolated from Pogonopus tubulosus (DC.) Schumann. Tubulosine is an ATP-competitive, selective *JAK3* inhibitor with an IC₅₀ value of 9.9 nM. Tubulosine also inhibits the kinase activities of other JAK family members, the extent of inhibition is less than that of JAK3, with IC₅₀ values of 69.5, 84.9 and 76.3 nM for JAK1, JAK2 and TYK2, respectively. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. Tubulosine induces apoptotic and necrotic/autophagic cell death. Tubulosine inhibits the process of peptide chain elongation by eukaryotic polysomes by, specifically preventing the elongation-factor-2-dependent step of translocation. Tubulosine exhibits anticancer activity in breast cancer cells .

Species:	Human (15)
Tag:	His (11) Strep (1) Tag Free (1) Avi (4) GST (7)
Source:	sf9 insect cells (1) P. pastoris (2) Sf9 insect cells (10) E. coli (2)

Cat. No.	Compare	Nombre del producto	Species	Source	Image

HY-P702721

	JAK3 Protein, Human (Active, sf9, GST) JAK3; Janus kinase 3; tyrosine-protein kinase JAK3; JAK 3; JAK3_HUMAN; JAKL; L JAK; leukocyte Janus kinase; LJAK; tyrosine protein kinase JAK3; Janus kinase 3 (a protein tyrosine kinase, leukocyte); JAK-3; L-JAK	Human	Sf9 insect cells
	JAK3 Protein, Human (sf9, GST) is the recombinant human-derived JAK3, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P700583

	JAK1 Protein, Human (P. pastoris, His) 4 Publications Verification JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	Human	P. pastoris
	JAK1 protein is a non-receptor tyrosine kinase that plays a crucial role in IFN-α/β/γ signaling and serves as a kinase partner for IL-2 and IL-10 receptors. It cooperates with the type I interferon receptor IFNAR2 to phosphorylate and activate IFNAR2 upon interferon binding to IFNAR1-IFNAR2. JAK1 Protein, Human (P. pastoris, His) is the recombinant human-derived JAK1 protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P701102

	*Janus kinase* 2/JAK2 Protein, Human (381a.a, His)** 1 Publications Verification JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase JAK2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P706063

	JAK1 Protein, Human (Active, sf9, His-GST) Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1; JAK1A; JAK1B	Human	Sf9 insect cells

HY-P7989

	*Janus kinase* 2/JAK2 Protein, Human (His)** 2 Publications Verification JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P705710

	JAK3 Protein, Human (Biotinylated, Inactive, sf9, Avi-His) Tyrosine-protein kinase JAK3; EC:2.7.10.2; Janus kinase 3 (JAK-3); Leukocyte janus kinase (L-JAK); JAK3	Human	Sf9 insect cells

HY-P706033

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706061

	*Janus kinase* 2/JAK2 Protein, Human (Active, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P704597

	*Janus kinase* 2/JAK2 Protein, Human (Biotinylated, sf9, Avi)** JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3	Human	Sf9 insect cells
	The Janus kinase 2 (JAK2) protein is a critical non-receptor tyrosine kinase that drives important cellular processes affecting growth, development, differentiation, and histone modifications. JAK2 plays a role in innate and adaptive immunity, interacting with receptors such as growth hormone, erythropoietin, and interleukins. Janus kinase 2/JAK2 Protein, Human (Biotinylated, sf9) is the recombinant human-derived Janus kinase 2/JAK2 protein, expressed by Sf9 insect cells, with tag free.

HY-P705571

	JAK1 Protein, Human (Active, sf9, GST) Tyrosine-protein kinase JAK1; Janus kinase 1 (JAK-1); JAK1A, JAK1B; EC:2.7.10.2	Human	Sf9 insect cells

HY-P706060

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, V617F, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706062

	*Janus kinase* 2/JAK2 Protein, Human (Active, JH2-JH1, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P705709

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, V617F, sf9, StrepII, His, Avi)** Tyrosine-protein kinase JAK2; EC:2.7.10.2; Janus kinase 2 (JAK-2); JAK2	Human	Sf9 insect cells

HY-P705808

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, Biotinylated, V617F, sf9, Avi)** JAK2, Janus kinase 2	Human	sf9 insect cells

HY-P71785

	SOCS1 Protein, Human (P.pastoris, His) CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3	Human	P. pastoris
	The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto	Chemical Structure

HY-117287

Deucravacitinib

Maximum Cited Publications

33 Publications Verification

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-131968

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-153701S

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-169326S

JAK2-IN-11
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-103018S

Gusacitinib-d4

Gusacitinib-d₄ (ASN-002-d₄) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-169984S

Tyk2-IN-22-d3
Tyk2-IN-22-d3 (Compound 1) is the deuterated analog of Tyk2-IN-22 (HY-168339). Tyk2-IN-22 (Compound A8) is a selective inhibitor for *tyrosine kinase* 2 (Tyk2), that it inhibits Tyk2, JAK1, and JAK3 with IC₅₀s of 9.7, 148.6, and 883.3 nM, respectively. Tyk2-IN-22 inhibits the downstream STAT5** phosphorylation .

Host:	Mouse (4) Rabbit (8)
Reactivity:	Human (12) Rat (7) Mouse (7)
Application:	IHC-P (5) ICC/IF (9) IF-Tissue (1) IP (6) IHC-F (1) WB (11) FC (2) ELISA (2)
Isotype:	IgG (7) IgG/Kappa (1) IgG2a (2)
Conjugation:	Non-conjugated (12) Biotin (3)
Clonality:	Polyclonal (1) Monoclonal (9) Recombinant (4)
Modification:	Phosphorylated (1) Unmodified (9)

Cat. No.	Compare	Nombre del producto	Application	Reactivity	Image

HY-P82721

	JAK3 Antibody (YA2466) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, ICC/IF	Human
	JAK3 Antibody (YA2466) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK3.

HY-P85234

	JAK3 Antibody (YA4926) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue	Human
	JAK3 Antibody (YA4926) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to JAK3.

HY-P86474

	JAK3 Antibody (YA6166) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK	WB, ICC/IF, IP, ELISA	Human
	JAK3 Antibody (YA6166) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK3.

HY-P80727

	JAK2 Antibody (YA330) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80726

	JAK1 Antibody (YA722) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
	JAK1 Antibody (YA722) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to JAK1.

HY-P85716

	JAK3 Antibody (YA5408) Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte janus kinase; L-JAK;	IHC-P	Human, Mouse, Rat
	JAK3 Antibody (YA5408) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to JAK3.

HY-P80726A

	JAK1 Antibody (YA722)(PBS only) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
	JAK1 Antibody (YA722) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to JAK1.

HY-P80829

	Phospho-JAK2 (Tyr1007/1008) Antibody JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P80727A

	JAK2 Antibody (YA330)(PBS only) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80829A

	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P86385

	JAK2 Antibody (YA6077) Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	JAK2 Antibody (YA6077) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P85598

	JNK1 Antibody (YA5290) AI849689; c Jun N terminal kinase 1; C-JUN kinase 1; c-Jun N-terminal kinase 1; JAK 1A; JAK1A; JNK 1; JNK 46; JNK; JNK-46; JNK1A2; JNK21B1/2; MAP kinase 8; MAPK 8; MAPK8; Mitogen activated protein kinase 8; Mitogen-activated protein kinase 8; MK08_HUMAN; p54 gamma; PRKM 8; PRKM8; Protein kinase JNK1; Protein kinase, mitogen-activated, 8; SAPK 1; SAPK gamma; SAPK1; Stress activated protein kinase JNK1; Stress-activated protein kinase 1; Stress-activated protein kinase JNK1; Tyrosine protein kinase JAK1 .	WB, ICC/IF	Human, Mouse, Rat
	JNK1 Antibody (YA5290) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to JNK1.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Añadir al carrito Obtener un presupuesto

Cat. No.	Nombre del producto		Classification

HY-174636

Human IL15 mRNA		mRNA Interleukin & Receptors
Human IL15 mRNA encodes the human interleukin 15 (IL15) protein, a cytokine that regulates T and natural killer cell activation and proliferation. IL15 induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6.

HY-174638

Human IL13RA1 mRNA		mRNA Interleukin & Receptors
Human IL13RA1 mRNA encodes the human interleukin 13 receptor subunit alpha 1 (IL13RA1) protein, a subunit of the interleukin 13 receptor. IL13RA1 serves as a primary IL13-binding subunit of the IL13 receptor, and may also be a component of IL4 receptors. It has been shown to bind tyrosine kinase TYK2, and thus may mediate the signaling processes that lead to the activation of JAK1, STAT3 and STAT6 induced by IL13 and IL4.

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones